248 related articles for article (PubMed ID: 19150225)
21. Steady-state pharmacokinetics and pharmacodynamics of piperacillin/tazobactam administered by prolonged infusion in hospitalised patients.
Shea KM; Cheatham SC; Wack MF; Smith DW; Sowinski KM; Kays MB
Int J Antimicrob Agents; 2009 Nov; 34(5):429-33. PubMed ID: 19726163
[TBL] [Abstract][Full Text] [Related]
22. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy.
Lodise TP; Lomaestro B; Drusano GL
Clin Infect Dis; 2007 Feb; 44(3):357-63. PubMed ID: 17205441
[TBL] [Abstract][Full Text] [Related]
23. Continuous versus intermittent piperacillin/tazobactam infusion in infection due to or suspected pseudomonas aeruginosa.
Cotrina-Luque J; Gil-Navarro MV; Acosta-García H; Alfaro-Lara ER; Luque-Márquez R; Beltrán-García M; Bautista-Paloma FJ
Int J Clin Pharm; 2016 Feb; 38(1):70-9. PubMed ID: 26474861
[TBL] [Abstract][Full Text] [Related]
24. Prolonged vs intermittent infusion of piperacillin/tazobactam in critically ill patients: a narrative and systematic review.
Yusuf E; Spapen H; Piérard D
J Crit Care; 2014 Dec; 29(6):1089-95. PubMed ID: 25179412
[TBL] [Abstract][Full Text] [Related]
25. Continuous infusion of piperacillin/tazobactam in patients with severe infections: A possible pharmacokinetic optimisation?
Attivi D; Gibaud S
Ann Pharm Fr; 2014 May; 72(3):146-51. PubMed ID: 24780830
[TBL] [Abstract][Full Text] [Related]
26. Treatment of ventilator-associated pneumonia with piperacillin-tazobactam/amikacin versus ceftazidime/amikacin: a multicenter, randomized controlled trial. VAP Study Group.
Brun-Buisson C; Sollet JP; Schweich H; Brière S; Petit C
Clin Infect Dis; 1998 Feb; 26(2):346-54. PubMed ID: 9502454
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study.
Chastre J; Wunderink R; Prokocimer P; Lee M; Kaniga K; Friedland I
Crit Care Med; 2008 Apr; 36(4):1089-96. PubMed ID: 18379232
[TBL] [Abstract][Full Text] [Related]
28. Does de-escalation of antibiotic therapy for ventilator-associated pneumonia affect the likelihood of recurrent pneumonia or mortality in critically ill surgical patients?
Eachempati SR; Hydo LJ; Shou J; Barie PS
J Trauma; 2009 May; 66(5):1343-8. PubMed ID: 19430237
[TBL] [Abstract][Full Text] [Related]
29. Optimization of continuous infusion of piperacillin-tazobactam in children with fever and neutropenia.
Delvallée M; Mazingue F; Abouchahla W; Delebarre M; Wallet F; Courcol R; Kipnis E; Dessein R
Pediatr Infect Dis J; 2013 Sep; 32(9):962-4. PubMed ID: 23629023
[TBL] [Abstract][Full Text] [Related]
30. Outcomes of extended-infusion piperacillin-tazobactam: a retrospective analysis of critically ill patients.
Lee GC; Liou H; Yee R; Quan CF; Neldner K
Clin Ther; 2012 Dec; 34(12):2297-300. PubMed ID: 23195962
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of an alternative extended-infusion piperacillin-tazobactam dosing strategy for the treatment of gram-negative infections.
Winstead EM; Ratliff PD; Hickson RP; Mueller JE; Judd WR
Int J Clin Pharm; 2016 Oct; 38(5):1087-93. PubMed ID: 27333796
[TBL] [Abstract][Full Text] [Related]
32. Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection.
Li C; Kuti JL; Nightingale CH; Mansfield DL; Dana A; Nicolau DP
J Antimicrob Chemother; 2005 Aug; 56(2):388-95. PubMed ID: 16002420
[TBL] [Abstract][Full Text] [Related]
33. Medical resource utilization among patients with ventilator-associated pneumonia: pooled analysis of randomized studies of doripenem versus comparators.
Kollef MH; Nathwani D; Merchant S; Gast C; Quintana A; Ketter N
Crit Care; 2010; 14(3):R84. PubMed ID: 20459721
[TBL] [Abstract][Full Text] [Related]
34. Clinical effectiveness of cefoperazone-sulbactam vs. piperacillin-tazobactam for the treatment of pneumonia in elderly patients.
Huang CT; Chen CH; Chen WC; Wang YT; Lai CC; Fu PK; Kuo LK; Chen CM; Fang WF; Tu CY; Ku SC
Int J Antimicrob Agents; 2022 Jan; 59(1):106491. PubMed ID: 34871744
[TBL] [Abstract][Full Text] [Related]
35. Hospital Length of Stay Among Patients Receiving Intermittent Versus Prolonged Piperacillin/Tazobactam Infusion in the Intensive Care Units.
Chan JD; Dellit TH; Lynch JB
J Intensive Care Med; 2018 Feb; 33(2):134-141. PubMed ID: 28486867
[TBL] [Abstract][Full Text] [Related]
36. Clinical Effect and Efficacy Factors of Modified Piperacillin-Tazobactam Dosing Regimens in Abdominal Tumor Patients with Post-Operative Pneumonia.
Yang Y; Lu Y; He X; Zhao H; Wang D; Wang W
Surg Infect (Larchmt); 2017; 18(2):99-104. PubMed ID: 27696986
[TBL] [Abstract][Full Text] [Related]
37. Population Pharmacokinetics and Pharmacodynamics of Piperacillin/Tazobactam in Patients with Nosocomial Infections.
Chen R; Qian Q; Sun MR; Qian CY; Zou SL; Wang ML; Wang LY
Eur J Drug Metab Pharmacokinet; 2016 Aug; 41(4):363-72. PubMed ID: 25894901
[TBL] [Abstract][Full Text] [Related]
38. Evaluating outcomes associated with alternative dosing strategies for piperacillin/tazobactam: a qualitative systematic review.
Mah GT; Mabasa VH; Chow I; Ensom MH
Ann Pharmacother; 2012 Feb; 46(2):265-75. PubMed ID: 22274145
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetic evaluation of piperacillin-tazobactam.
Hayashi Y; Roberts JA; Paterson DL; Lipman J
Expert Opin Drug Metab Toxicol; 2010 Aug; 6(8):1017-31. PubMed ID: 20636224
[TBL] [Abstract][Full Text] [Related]
40. Extended infusion versus intermittent infusion of imipenem in the treatment of ventilator-associated pneumonia.
Ibrahim MM; Tammam TF; Ebaed MED; Sarhan HA; Gad GF; Hussein AK
Drug Des Devel Ther; 2017; 11():2677-2682. PubMed ID: 28919718
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]